La combinación de quimioterapia intravenosa e intraperitoneal mejora la supervivencia en el cáncer de ovario

Translated title of the contribution: The combination of intravenous and intraperitoneal chemotherapy improves survival for women ovarian cancer

Lucas Minig, Edward Trimble

Research output: Contribution to journalReview articlepeer-review

Abstract

There is compelling evidence from seven RCTs that a combination of intravenous (IV) and intraperitoneal (IP) chemotherapy given after optimal cytoreductive surgery significantly improves survival for women with FIGO stage III epithelial ovarian cancer. On the basis of this data, the US-NCI issued a Clinical Announcement in January 2006 recommending that women and their physicians consider such combined IV/IP chemotherapy where appropriate. Despite ongoing educational efforts, IP/IV regimens have not become the standard of care in many hospitals. Ongoing clinical research seeks to reduce the toxicity associated with IP chemotherapy while retaining efficacy and integrating new biological approaches to treatment. Copyrigth

Translated title of the contributionThe combination of intravenous and intraperitoneal chemotherapy improves survival for women ovarian cancer
Original languageSpanish
Pages (from-to)323-325
Number of pages3
JournalSalud(i)Ciencia
Volume18
Issue number4
StatePublished - Jun 1 2011
Externally publishedYes

Keywords

  • Chemotherapy
  • Epithelial ovarian cancer
  • Intraperitoneal chemotherapy
  • Treatment

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'The combination of intravenous and intraperitoneal chemotherapy improves survival for women ovarian cancer'. Together they form a unique fingerprint.

Cite this